Eli Lilly became the first pharmaceutical manufacturer to reach a US$1 trillion market capitalization.
The milestone occurred in 2024 as investors responded to strong demand for the company’s diabetes and obesity medicines, especially Mounjaro and Zepbound. These drugs belong to the incretin-based treatment category and helped transform expectations for Lilly’s future revenue.
Eli Lilly’s market capitalization reflects the value investors place on its publicly traded shares, not the company’s cash balance or annual sales. Market value can change substantially when share prices move, even if the number of shares remains broadly stable.
A common mix-up is calling Lilly the first healthcare company to reach US$1 trillion. The broader healthcare sector includes medical-device and technology companies, while Lilly’s distinction concerns a pharmaceutical manufacturer. The company was founded in Indianapolis in 1876 by Colonel Eli Lilly.